Tom Stitt retweeted
New blog post: Molecular Diagnostics: A Broken Business Model or Flawed Execution? link.medium.com/xuPijvAzI5 #cancer #cancertherapymonitoring #diagnostics
Tom Stitt retweeted
The Case for Real-Time Cancer Therapy Monitoring - Rapid identification of late-stage cancer patients who are not responding to drug therapy.
medium.com/@cadexgenomics/th…
Tom Stitt retweeted
Cadex Genomics provides real-time insight into therapy response for patients with stage IV solid tumors. “So far, Cadex’s technology is proving to be a game-changer for patients and their oncologists,” said Weiland.
medcitynews.com/2019/04/the-…
#cfDNA #cancertherapy
Tom Stitt retweeted
The doctor becomes the patient.
greenvillejournal.com/2019/0…
Tom Stitt retweeted
Cadex Genomics has been selected as a finalist in the Diagnostics category for the Pitch Perfect Startup Contest at the MedCity INVEST Event April 23-24 in Chicago, IL. cadexgenomics.com/news/5b2b7…
Tom Stitt retweeted
.@CadexGenomics’ founders, Bill Haack, Sudhir Sinha, Gary Spitzer and Greg Schafer, are creating cutting-edge tests to track #cancer patients’ therapy response. Check out how this stellar #startup team is revolutionizing diagnostics! https://nitter.cf/t.co/S6bVcf5nLs
Tom Stitt retweeted
Great to see Bay Area member @CadexGenomics presenting their Alibrex technology at our #Biocompartnering conference.
Tom Stitt retweeted
Landmark #TAILORx results demonstrate that the #Oncotype DX test identifies the 70% of women with early-stage #breastcancer who receive no benefit from chemo. Watch this video to learn more about the trial: youtube.com/watch?v=iucCGlpA…
Tom Stitt retweeted
This startup is focused on developing a #liquidbiopsy-based test to elucidate how patients may respond to certain #cancer therapies @CadexGenomics
goo.gl/APzU4s
Tom Stitt retweeted
Liquid biopsies can accurately track lung cancer treatment responses by measuring ctDNA during immunotherapy and related treatments – 2 @HopkinsKimmel studies hopkinsmedicine.org/news/new… via @HopkinsMedNews
Tom Stitt retweeted
"There is a growing need to match mutational analysis assays with a mutation agnostic diagnostic assay that can more rapidly guide and inform cancer therapy for a wide range of patients" @skopetz #cancer #diagnostic goo.gl/zGefWE
Tom Stitt retweeted
Great infographic: How Unsexy B2B Companies Are Using Social Media http://t.co/gMbVbTQiNM via @spiral16
Tom Stitt retweeted
Why we need better conference call etiquette: http://t.co/dkXLaO7ADK via @trippandtyler
Tom Stitt retweeted
Dear Shipping Trade Publications: It's Time to Put Logistics Startups on your Editorial Calendars buff.ly/Lss8t4
Tom Stitt retweeted
What is a CSC Certificate (Convention for Safe Containers) | Shipping Container Tech Talk staxxon.com/csc/
Tom Stitt retweeted
RT @bmkuehn: Medicine's big secret: "Evidence is often inconclusive & experts commonly disagree," says @hmkyale. n.pr/1dNKD1e
Tom Stitt retweeted
Collaborative Economy impacts to Supply Chain, Logistics, Shipping by @JonathanWich jonathanwichmann.com/my-list… Pass this to your ops team


















